Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 147

1.

Probing Arrestin Function Using Intramolecular FlAsH-BRET Biosensors.

Strungs EG, Luttrell LM, Lee MH.

Methods Mol Biol. 2019;1957:309-322. doi: 10.1007/978-1-4939-9158-7_19.

PMID:
30919362
2.

Transcriptomic characterization of signaling pathways associated with osteoblastic differentiation of MC-3T3E1 cells.

Luttrell LM, Dar MS, Gesty-Palmer D, El-Shewy HM, Robinson KM, Haycraft CJ, Barth JL.

PLoS One. 2019 Jan 4;14(1):e0204197. doi: 10.1371/journal.pone.0204197. eCollection 2019.

3.

β-Arrestin Based Receptor Signaling Paradigms: Potential Therapeutic Targets for Complex Age-Related Disorders.

van Gastel J, Hendrickx JO, Leysen H, Santos-Otte P, Luttrell LM, Martin B, Maudsley S.

Front Pharmacol. 2018 Nov 28;9:1369. doi: 10.3389/fphar.2018.01369. eCollection 2018. Review.

4.

Analysis of longitudinal semicontinuous data using marginalized two-part model.

Jaffa MA, Gebregziabher M, Garrett SM, Luttrell DK, Lipson KE, Luttrell LM, Jaffa AA.

J Transl Med. 2018 Nov 6;16(1):301. doi: 10.1186/s12967-018-1674-5.

5.

Manifold roles of β-arrestins in GPCR signaling elucidated with siRNA and CRISPR/Cas9.

Luttrell LM, Wang J, Plouffe B, Smith JS, Yamani L, Kaur S, Jean-Charles PY, Gauthier C, Lee MH, Pani B, Kim J, Ahn S, Rajagopal S, Reiter E, Bouvier M, Shenoy SK, Laporte SA, Rockman HA, Lefkowitz RJ.

Sci Signal. 2018 Sep 25;11(549). pii: eaat7650. doi: 10.1126/scisignal.aat7650.

PMID:
30254056
6.

GIT2-A keystone in ageing and age-related disease.

van Gastel J, Boddaert J, Jushaj A, Premont RT, Luttrell LM, Janssens J, Martin B, Maudsley S.

Ageing Res Rev. 2018 May;43:46-63. doi: 10.1016/j.arr.2018.02.002. Epub 2018 Feb 13. Review.

PMID:
29452267
7.

Plasma Connective Tissue Growth Factor (CTGF/CCN2) Levels Predict Myocardial Infarction in the Veterans Affairs Diabetes Trial (VADT) Cohort.

Hunt KJ, Jaffa MA, Garrett SM, Luttrell DK, Lipson KE, Lopes-Virella MF, Luttrell LM, Jaffa AA; VADT Investigators.

Diabetes Care. 2018 Apr;41(4):840-846. doi: 10.2337/dc17-2083. Epub 2018 Jan 30.

8.

The Diverse Roles of Arrestin Scaffolds in G Protein-Coupled Receptor Signaling.

Peterson YK, Luttrell LM.

Pharmacol Rev. 2017 Jul;69(3):256-297. doi: 10.1124/pr.116.013367. Review.

9.

Translating in vitro ligand bias into in vivo efficacy.

Luttrell LM, Maudsley S, Gesty-Palmer D.

Cell Signal. 2018 Jan;41:46-55. doi: 10.1016/j.cellsig.2017.05.002. Epub 2017 May 7. Review.

10.

S1P in HDL promotes interaction between SR-BI and S1PR1 and activates S1PR1-mediated biological functions: calcium flux and S1PR1 internalization.

Lee MH, Appleton KM, El-Shewy HM, Sorci-Thomas MG, Thomas MJ, Lopes-Virella MF, Luttrell LM, Hammad SM, Klein RL.

J Lipid Res. 2017 Feb;58(2):325-338. doi: 10.1194/jlr.M070706. Epub 2016 Nov 23.

11.

Multivariate Generalized Linear Mixed Models With Random Intercepts To Analyze Cardiovascular Risk Markers in Type-1 Diabetic Patients.

Jaffa MA, Gebregziabher M, Luttrell DK, Luttrell LM, Jaffa AA.

J Appl Stat. 2016;43(8):1447-1464. Epub 2015 Nov 26.

12.

GPCR Signaling Rides a Wave of Conformational Changes.

Luttrell LM.

Cell. 2016 Oct 20;167(3):602-603. doi: 10.1016/j.cell.2016.10.006.

13.

Angiotensin II receptors and peritoneal dialysis-induced peritoneal fibrosis.

Morinelli TA, Luttrell LM, Strungs EG, Ullian ME.

Int J Biochem Cell Biol. 2016 Aug;77(Pt B):240-50. doi: 10.1016/j.biocel.2016.04.016. Epub 2016 May 7. Review.

14.

The conformational signature of β-arrestin2 predicts its trafficking and signalling functions.

Lee MH, Appleton KM, Strungs EG, Kwon JY, Morinelli TA, Peterson YK, Laporte SA, Luttrell LM.

Nature. 2016 Mar 31;531(7596):665-8. doi: 10.1038/nature17154. Epub 2016 Mar 23.

15.

Plasma Prekallikrein Is Associated With Carotid Intima-Media Thickness in Type 1 Diabetes.

Jaffa MA, Luttrell D, Schmaier AH, Klein RL, Lopes-Virella M, Luttrell LM, Jaffa AA; DCCT/EDIC Research Group.

Diabetes. 2016 Feb;65(2):498-502. doi: 10.2337/db15-0930. Epub 2015 Nov 24.

16.

Exploring G protein-coupled receptor signaling networks using SILAC-based phosphoproteomics.

Williams GR, Bethard JR, Berkaw MN, Nagel AK, Luttrell LM, Ball LE.

Methods. 2016 Jan 1;92:36-50. doi: 10.1016/j.ymeth.2015.06.022. Epub 2015 Jul 6.

17.

Fulfilling the Promise of "Biased" G Protein-Coupled Receptor Agonism.

Luttrell LM, Maudsley S, Bohn LM.

Mol Pharmacol. 2015 Sep;88(3):579-88. doi: 10.1124/mol.115.099630. Epub 2015 Jul 1. Review.

18.

Informatic deconvolution of biased GPCR signaling mechanisms from in vivo pharmacological experimentation.

Maudsley S, Martin B, Janssens J, Etienne H, Jushaj A, van Gastel J, Willemsen A, Chen H, Gesty-Palmer D, Luttrell LM.

Methods. 2016 Jan 1;92:51-63. doi: 10.1016/j.ymeth.2015.05.013. Epub 2015 May 16.

19.

Inhibition of Sphingosine Kinase 1 Ameliorates Angiotensin II-Induced Hypertension and Inhibits Transmembrane Calcium Entry via Store-Operated Calcium Channel.

Wilson PC, Fitzgibbon WR, Garrett SM, Jaffa AA, Luttrell LM, Brands MW, El-Shewy HM.

Mol Endocrinol. 2015 Jun;29(6):896-908. doi: 10.1210/me.2014-1388. Epub 2015 Apr 14.

20.

Delineation of a conserved arrestin-biased signaling repertoire in vivo.

Maudsley S, Martin B, Gesty-Palmer D, Cheung H, Johnson C, Patel S, Becker KG, Wood WH 3rd, Zhang Y, Lehrmann E, Luttrell LM.

Mol Pharmacol. 2015 Apr;87(4):706-17. doi: 10.1124/mol.114.095224. Epub 2015 Jan 30.

21.

Novel mechanism of plasma prekallikrein (PK) activation by vascular smooth muscle cells: evidence of the presence of PK activator.

Keum JS, Jaffa MA, Luttrell LM, Jaffa AA.

J Biol Regul Homeost Agents. 2014 Oct-Dec;28(4):587-603.

22.

Stimulation of Cyclooxygenase 2 Expression in Rat Peritoneal Mesothelial Cells.

Ullian ME, Luttrell LM, Lee MH, Morinelli TA.

Nephron Exp Nephrol. 2014 Dec 17. [Epub ahead of print]

PMID:
25531215
23.

Arrestin-dependent angiotensin AT1 receptor signaling regulates Akt and mTor-mediated protein synthesis.

Kendall RT, Lee MH, Pleasant DL, Robinson K, Kuppuswamy D, McDermott PJ, Luttrell LM.

J Biol Chem. 2014 Sep 19;289(38):26155-66. doi: 10.1074/jbc.M114.595728. Epub 2014 Jul 31.

24.

Epidermal growth factor-induced proliferation of collecting duct cells from Oak Ridge polycystic kidney mice involves activation of Na+/H+ exchanger.

Coaxum SD, Blanton MG, Joyner A, Akter T, Bell PD, Luttrell LM, Raymond JR Sr, Lee MH, Blichmann PA, Garnovskaya MN, Saigusa T.

Am J Physiol Cell Physiol. 2014 Sep 15;307(6):C554-60. doi: 10.1152/ajpcell.00188.2014. Epub 2014 Jul 23.

25.

Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery.

Luttrell LM.

Mol Endocrinol. 2014 Mar;28(3):281-94. doi: 10.1210/me.2013-1314. Epub 2014 Jan 16. Review.

26.

Arrestin-dependent activation of ERK and Src family kinases.

Strungs EG, Luttrell LM.

Handb Exp Pharmacol. 2014;219:225-57. doi: 10.1007/978-3-642-41199-1_12.

PMID:
24292833
27.

Preface. The molecular biology of arrestins.

Luttrell LM.

Prog Mol Biol Transl Sci. 2013;118:xv. doi: 10.1016/B978-0-12-394440-5.10000-2. No abstract available.

PMID:
23764066
28.

Arrestin pathways as drug targets.

Luttrell LM.

Prog Mol Biol Transl Sci. 2013;118:469-97. doi: 10.1016/B978-0-12-394440-5.00018-8. Review.

PMID:
23764065
29.

Arrestins as regulators of kinases and phosphatases.

Luttrell LM, Miller WE.

Prog Mol Biol Transl Sci. 2013;118:115-47. doi: 10.1016/B978-0-12-394440-5.00005-X. Review.

PMID:
23764052
30.

The arrestin-selective angiotensin AT1 receptor agonist [Sar1,Ile4,Ile8]-AngII negatively regulates bradykinin B2 receptor signaling via AT1-B2 receptor heterodimers.

Wilson PC, Lee MH, Appleton KM, El-Shewy HM, Morinelli TA, Peterson YK, Luttrell LM, Jaffa AA.

J Biol Chem. 2013 Jun 28;288(26):18872-84. doi: 10.1074/jbc.M113.472381. Epub 2013 May 9.

31.

Textrous!: extracting semantic textual meaning from gene sets.

Chen H, Martin B, Daimon CM, Siddiqui S, Luttrell LM, Maudsley S.

PLoS One. 2013 Apr 30;8(4):e62665. doi: 10.1371/journal.pone.0062665. Print 2013.

32.

Relationship between vitamin D status and incidence of vascular events in the Veterans Affairs Diabetes Trial.

Alele JD, Luttrell LM, Hollis BW, Luttrell DK, Hunt KJ; VADT Study Group.

Atherosclerosis. 2013 Jun;228(2):502-7. doi: 10.1016/j.atherosclerosis.2013.03.024. Epub 2013 Apr 4.

PMID:
23608249
33.

Angiotensin II activates NF-κB through AT1A receptor recruitment of β-arrestin in cultured rat vascular smooth muscle cells.

Morinelli TA, Lee MH, Kendall RT, Luttrell LM, Walker LP, Ullian ME.

Am J Physiol Cell Physiol. 2013 Jun 15;304(12):C1176-86. doi: 10.1152/ajpcell.00235.2012. Epub 2013 Apr 10.

34.

Emergent biological properties of arrestin pathway-selective biased agonism.

Appleton KM, Luttrell LM.

J Recept Signal Transduct Res. 2013 Jun;33(3):153-61. doi: 10.3109/10799893.2013.769004. Epub 2013 Feb 28.

PMID:
23448506
35.

Biasing the parathyroid hormone receptor: relating in vitro ligand efficacy to in vivo biological activity.

Appleton KM, Lee MH, Alele C, Alele C, Luttrell DK, Peterson YK, Morinelli TA, Luttrell LM.

Methods Enzymol. 2013;522:229-62. doi: 10.1016/B978-0-12-407865-9.00013-3.

PMID:
23374189
36.

A high-content, live-cell, and real-time approach to the quantitation of ligand-induced β-Arrestin2 and Class A/Class B GPCR mobilization.

Leonard AP, Appleton KM, Luttrell LM, Peterson YK.

Microsc Microanal. 2013 Feb;19(1):150-70. doi: 10.1017/S1431927612014067. Epub 2013 Jan 28.

37.

Endocrine function in aging.

Cai H, McNeilly AS, Luttrell LM, Martin B.

Int J Endocrinol. 2012;2012:872478. doi: 10.1155/2012/872478. Epub 2012 Dec 30. No abstract available.

38.

β-arrestin-selective G protein-coupled receptor agonists engender unique biological efficacy in vivo.

Gesty-Palmer D, Yuan L, Martin B, Wood WH 3rd, Lee MH, Janech MG, Tsoi LC, Zheng WJ, Luttrell LM, Maudsley S.

Mol Endocrinol. 2013 Feb;27(2):296-314. doi: 10.1210/me.2012-1091. Epub 2013 Jan 11.

39.

Functional signaling biases in G protein-coupled receptors: Game Theory and receptor dynamics.

Maudsley S, Patel SA, Park SS, Luttrell LM, Martin B.

Mini Rev Med Chem. 2012 Aug;12(9):831-40. Review.

40.

Low-density lipoprotein induced expression of connective tissue growth factor via transactivation of sphingosine 1-phosphate receptors in mesangial cells.

El-Shewy HM, Sohn M, Wilson P, Lee MH, Hammad SM, Luttrell LM, Jaffa AA.

Mol Endocrinol. 2012 May;26(5):833-45. doi: 10.1210/me.2011-1261. Epub 2012 Mar 15.

41.

Phospholipase C and protein kinase C-β 2 mediate insulin-like growth factor II-dependent sphingosine kinase 1 activation.

El-Shewy HM, Abdel-Samie SA, Al Qalam AM, Lee MH, Kitatani K, Anelli V, Jaffa AA, Obeid LM, Luttrell LM.

Mol Endocrinol. 2011 Dec;25(12):2144-56. doi: 10.1210/me.2011-0101. Epub 2011 Oct 20.

42.

Refining efficacy: exploiting functional selectivity for drug discovery.

Gesty-Palmer D, Luttrell LM.

Adv Pharmacol. 2011;62:79-107. doi: 10.1016/B978-0-12-385952-5.00009-9. Review.

PMID:
21907907
43.

Refining efficacy: allosterism and bias in G protein-coupled receptor signaling.

Luttrell LM, Kenakin TP.

Methods Mol Biol. 2011;756:3-35. doi: 10.1007/978-1-61779-160-4_1. Review.

PMID:
21870218
44.

Increased expression of beta-arrestin 1 and 2 in murine models of rheumatoid arthritis: isoform specific regulation of inflammation.

Li P, Cook JA, Gilkeson GS, Luttrell LM, Wang L, Borg KT, Halushka PV, Fan H.

Mol Immunol. 2011 Oct;49(1-2):64-74. doi: 10.1016/j.molimm.2011.07.021. Epub 2011 Aug 19.

45.

Brave new world? Arrestin pathway bias in drug design.

Andresen BT, Luttrell LM.

Endocr Metab Immune Disord Drug Targets. 2011 Jun;11(2):90-1. No abstract available.

PMID:
21599621
46.

'Biasing' the parathyroid hormone receptor: a novel anabolic approach to increasing bone mass?

Gesty-Palmer D, Luttrell LM.

Br J Pharmacol. 2011 Sep;164(1):59-67. doi: 10.1111/j.1476-5381.2011.01450.x. Review.

47.

The beta-arrestin pathway-selective type 1A angiotensin receptor (AT1A) agonist [Sar1,Ile4,Ile8]angiotensin II regulates a robust G protein-independent signaling network.

Kendall RT, Strungs EG, Rachidi SM, Lee MH, El-Shewy HM, Luttrell DK, Janech MG, Luttrell LM.

J Biol Chem. 2011 Jun 3;286(22):19880-91. doi: 10.1074/jbc.M111.233080. Epub 2011 Apr 18.

48.

Plasma kallikrein promotes epidermal growth factor receptor transactivation and signaling in vascular smooth muscle through direct activation of protease-activated receptors.

Abdallah RT, Keum JS, El-Shewy HM, Lee MH, Wang B, Gooz M, Luttrell DK, Luttrell LM, Jaffa AA.

J Biol Chem. 2010 Nov 5;285(45):35206-15. doi: 10.1074/jbc.M110.171769. Epub 2010 Sep 8. Erratum in: J Biol Chem. 2011 Jul 1;286(26):23620. El-Shewy, Hesham M [added].

49.

Novel mechanisms in the regulation of G protein-coupled receptor trafficking to the plasma membrane.

Tholanikunnel BG, Joseph K, Kandasamy K, Baldys A, Raymond JR, Luttrell LM, McDermott PJ, Fernandes DJ.

J Biol Chem. 2010 Oct 29;285(44):33816-25. doi: 10.1074/jbc.M110.168229. Epub 2010 Aug 25.

50.

Bradykinin decreases podocyte permeability through ADAM17-dependent epidermal growth factor receptor activation and zonula occludens-1 rearrangement.

Dey M, Baldys A, Sumter DB, Göoz P, Luttrell LM, Raymond JR, Göoz M.

J Pharmacol Exp Ther. 2010 Sep 1;334(3):775-83. doi: 10.1124/jpet.110.168054. Epub 2010 Jun 21.

Supplemental Content

Loading ...
Support Center